CEO Pfizer’s revelation about COVID vaccine

Vaccines

Getty Images

CEO Pfizer says a third coronavirus vaccine is not ruled out.

Pfizer CEO Albert Bourla said those who received the two doses of COVID-19 vaccine were likely to need a third dose to boost the drug’s effectiveness.

As reported by CNN, Bourla made these remarks at a CBS Health forum. In a dialogue with his colleagues, the CEO of Pfizer said that the evidence shows that the coronavirus vaccine is losing its effectiveness over the months. Therefore, a third dose may be required.

“A probable scenario is that a third dose will probably be needed sometime between six and 12 months and then there will be a revaccination. But all this must be confirmed, “said Bourla.

“If you ask me, I think revaccination will be needed based on this data,” Pfizer CEO added.

It should be noted that Bourla’s words are not official. It is a forecast based on data available to the leader of the pharmaceutical company.

Pfizer has already announced that its vaccine will guarantee 95% efficacy against serious hospitalizations for up to six months after the second dose. This study involved 12,000 vaccinated patients. The company’s scientific team emphasized the partial and probable nature of the results.

The United States is evaluating strengthening vaccine doses

In line with the concerns of Pfizer and the rest of the pharmaceutical companies, the US government is evaluating the possibility of applying a third dose of coronavirus vaccine.

This was confirmed by David Kessler, scientific director of response against COVID-19 of the Joe Biden administration.

Kessler said new variants of the coronavirus could “challenge” the effectiveness of vaccines.

“It seems strong, but there is a certain decline and certainly the variants cause … they make these vaccines work more. So I think, for planning purposes, just for planning purposes, I think we should expect to have to move on, “he told the House Select on Coronavirus Response subcommittee.

The United States will invest millions to detect new variants of COVID-19

The Joe Biden government will invest $ 1.7 billion to detect new variants of the coronavirus in the United States.

The amount will come out of the American Rescue Plan through the Centers for Disease Control and Prevention (CDC). It will target different states to detect early the circulation of new variants of the disease.

It is an ambitious plan that consists in following the genomic sequence of the viruses registered in different infected. The United States is already engaged in these studies. The Biden government has allocated $ 200 million, equivalent to 29,000 genomic sequences per week.

The new funding would require more work capacity. It would also give states the opportunity to have their own resources to conduct their studies without depending on the CDC headquarters.

READ MORE: Joe Biden begins restoring abortion restrictions: what steps has he taken?

Follow the same on Instagram now


.Source